Fort Collins, Colo., and Golden, Colo. — Oct. 12, 2010 – Inviragen and PharmaJet announced the award of a five-year, $15.5 million dollar contract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to advance the development of a needle-free, easy-to-administer dengue vaccine.
